Barclays lowered the firm’s price target on Orchestra BioMed (OBIO) to $11 from $12 and keeps an Overweight rating on the shares. The firm says the company highlighted clinical and strategic achievements when reporting Q3.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OBIO:
- Orchestra BioMed reports Q3 EPS (40c), consensus (43c)
- Orchestra BioMed files to sell 8.03M shares of common stock for holders
- Orchestra BioMed Secures $147M for Therapy Advancements
- Orchestra BioMed Announces Strategic Agreement with Terumo
- Orchestra BioMed, Terumo enter new $30M Virtue SAB agreements